BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BioLife Solutions (NASDAQ: BLFS), a leading supplier of bioproduction tools for the cell and gene therapy market, has appointed Cathy Coste to its board of directors, expanding the board to seven members. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who remains a director and committee member.
Coste brings over 40 years of senior executive experience, including 30+ years at Deloitte where she served as a senior partner and life sciences industry executive leader. She has worked with more than two dozen life sciences companies and currently serves as audit committee chair for Biomerica, Minerva Surgical, and Renalytix plc.
The appointment comes as BioLife completes its transition to a pure-play enabler of cell and gene therapies, positioning the company for revenue growth and sustained profitability.
BioLife Solutions (NASDAQ: BLFS), un fornitore leader di strumenti per la bioproduzione nel mercato della terapia cellulare e genica, ha nominato Cathy Coste nel suo consiglio di amministrazione, ampliando il consiglio a sette membri. Coste assumerà il ruolo di presidente del comitato di audit, sostituendo Joydeep Goswami, che rimane un direttore e membro del comitato.
Coste porta con sé oltre 40 anni di esperienza come dirigente senior, inclusi più di 30 anni in Deloitte, dove ha ricoperto il ruolo di partner senior e leader nel settore delle scienze della vita. Ha collaborato con oltre due dozzine di aziende nel campo delle scienze della vita e attualmente è presidente del comitato di audit per Biomerica, Minerva Surgical e Renalytix plc.
Questa nomina arriva mentre BioLife completa la sua transizione verso un'azienda focalizzata esclusivamente sulle terapie cellulari e geniche, posizionando l'azienda per una crescita dei ricavi e una redditività sostenuta.
BioLife Solutions (NASDAQ: BLFS), un proveedor líder de herramientas de bioproducción para el mercado de terapia celular y génica, ha nombrado a Cathy Coste en su junta directiva, ampliando la junta a siete miembros. Coste asumirá el cargo de presidenta del comité de auditoría, reemplazando a Joydeep Goswami, quien sigue siendo director y miembro del comité.
Coste aporta más de 40 años de experiencia ejecutiva senior, incluidos más de 30 años en Deloitte, donde se desempeñó como socia senior y líder ejecutiva en la industria de ciencias de la vida. Ha trabajado con más de dos docenas de empresas de ciencias de la vida y actualmente es presidenta del comité de auditoría de Biomerica, Minerva Surgical y Renalytix plc.
El nombramiento se produce mientras BioLife completa su transición a un habilitador puramente enfocado en terapias celulares y génicas, posicionando a la empresa para el crecimiento de ingresos y una rentabilidad sostenida.
BioLife Solutions (NASDAQ: BLFS)는 세포 및 유전자 치료 시장을 위한 생물 생산 도구의 선도적인 공급업체로서 Cathy Coste를 이사회에 임명하여 이사회를 7명으로 확대했습니다. Coste는 Joydeep Goswami를 대신하여 감사위원회 의장으로 활동하며, Goswami는 여전히 이사이자 위원회 멤버로 남아 있습니다.
Coste는 40년 이상의 고위 경영 경험을 보유하고 있으며, 그 중 30년 이상을 Deloitte에서 파트너 고위직 및 생명 과학 산업의 리더로 활동했습니다. 그녀는 20개 이상의 생명 과학 기업과 협력했으며 현재 Biomerica, Minerva Surgical 및 Renalytix plc의 감사위원회 의장으로 활동하고 있습니다.
이번 임명은 BioLife가 세포 및 유전자 치료의 순수한 지원자로서의 전환을 완료하면서 이루어졌으며, 이는 회사의 수익 성장과 지속 가능한 수익성을 위한 포지셔닝을 의미합니다.
BioLife Solutions (NASDAQ: BLFS), un fournisseur de premier plan d'outils de bioproduction pour le marché de la thérapie cellulaire et génique, a nommé Cathy Coste au sein de son conseil d'administration, portant le nombre de membres à sept. Coste sera présidente du comité d'audit, remplaçant Joydeep Goswami, qui reste directeur et membre du comité.
Coste apporte plus de 40 ans d'expérience en tant que cadre supérieur, dont plus de 30 ans chez Deloitte, où elle a été associée senior et leader dans l'industrie des sciences de la vie. Elle a travaillé avec plus de deux douzaines d'entreprises dans le domaine des sciences de la vie et est actuellement présidente du comité d'audit de Biomerica, Minerva Surgical et Renalytix plc.
Cette nomination intervient alors que BioLife achève sa transition vers un acteur exclusivement dédié aux thérapies cellulaires et géniques, positionnant ainsi l'entreprise pour une croissance des revenus et une rentabilité durable.
BioLife Solutions (NASDAQ: BLFS), ein führender Anbieter von Bioproduktionstools für den Markt der Zell- und Gentherapie, hat Cathy Coste in seinen Vorstand berufen und damit den Vorstand auf sieben Mitglieder erweitert. Coste wird den Vorsitz des Prüfungsausschusses übernehmen und Joydeep Goswami ersetzen, der weiterhin Direktor und Ausschussmitglied bleibt.
Coste bringt über 40 Jahre Erfahrung in leitenden Positionen mit, darunter mehr als 30 Jahre bei Deloitte, wo sie als Senior Partnerin und Führungskraft in der Biowissenschaftsbranche tätig war. Sie hat mit mehr als zwei Dutzend Unternehmen im Bereich Biowissenschaften zusammengearbeitet und ist derzeit Vorsitzende des Prüfungsausschusses von Biomerica, Minerva Surgical und Renalytix plc.
Die Ernennung erfolgt, während BioLife seinen Übergang zu einem reinen Anbieter von Zell- und Gentherapien abschließt, was das Unternehmen für Umsatzwachstum und nachhaltige Rentabilität positioniert.
- Appointment of highly qualified financial expert with 40+ years of senior executive experience
- Extensive life sciences industry expertise through work with 25+ companies
- Completion of transition to pure-play CGT enabler
- Company positioned for revenue growth and sustained profitability
- None.
"Cathy is a highly qualified financial professional with substantial expertise in audits, risk and controls, and compliance, making her ideal to serve as chair of our audit committee," said Roderick de Greef, BioLife Chairman and CEO. "She brings to the BioLife board more than four decades as a senior executive with experience ranging from high-growth private companies to complex global public companies. At Deloitte, she worked with more than two dozen life sciences companies, while her service as an independent director and audit chair affords a wealth of experience in governance initiatives, strategic planning and organizational development."
"This is an exciting and pivotal time to join the board at BioLife," said Ms. Coste. "With the transition to a pure-play enabler of cell and gene therapies now complete, the company is well-positioned for revenue growth and sustained profitability. I look forward to contributing to BioLife's future success."
Ms. Coste retired from Deloitte in 2020, where she most recently was a senior partner and life sciences industry executive leader. With Deloitte for more than 30 years, she served in corporate and professional services positions, ultimately leading global finance, internal audit and operations teams while participating in more than 200 audit committee meetings. Previously she worked at Mervyn's, including responsibility in accounting, FP&A and operations.
Ms. Coste is a director of Biomerica, Inc., Minerva Surgical, Inc. (a public company that went private in 2024) and Renalytix plc, serving as audit committee chair for each. She holds a B.A. in business administration-accounting from California State University, Hayward, and completed Harvard Business School's Corporate Director's Certificate Program. She is a licensed Certified Public Accountant.
About BioLife Solutions
BioLife Solutions is a leading supplier of cell processing tools and services for the cell and gene therapy (CGT) market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, storage and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.
Contacts:
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-appoints-cathy-coste-as-director-and-audit-committee-chair-302403979.html
SOURCE BioLife Solutions, Inc.
FAQ
When did BioLife Solutions (BLFS) appoint Cathy Coste to its board of directors?
What positions will Cathy Coste hold at BioLife Solutions (BLFS)?
How many years of experience does Cathy Coste bring to BioLife Solutions (BLFS)?
What is BioLife Solutions' (BLFS) current business focus?
How many members are now on BioLife Solutions' (BLFS) board of directors?
